Myomectomy Market is Expected to Grow at a CAGR of 6.9% till 2023 | Asserts MRFR

MRFR s Detailed Study Provides Monitoring Myomectomy Market by Scope, Applications, Products, Key Players, Emerging Trends, Sales, Revenue, And Market Share and Growth Rate.

Pune, India - March 7, 2019 /MarketersMedia/ —

Market Highlights:

Myomectomy is surgical procedure for the removal of uterine fibroids. Uterine fibroid, also known as leiomyoma or myomas, is a non-cancerous growth that develops inside or on the wall of a woman s uterus. Heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramps are major symptoms for uterine fibroids.

Prevalence of uterine disorders abnormal uterine bleeding (AUB), amenorrhea, dysmenorrhea (painful menstrual periods, and premenstrual syndrome (PMS) is on the rise across the globe, especially in the developing countries. In addition, increasing research and development activities, and technological advancements to identify the causes and risk factors for such disorders is fuelling the global myomectomy market growth. There is also an increasing demand for technologically advanced devices for the diagnosis of uterine fibroids. Increasing awareness about the reproductive health, and diseases among women across the globe also determine the growth of the market. The key players are now focusing on the geographical expansion in the developing regions such as Asia Pacific.

Uterine fibroids affects nearly 40% of women in the age group of 30 and 55, including 20 million women in North America and 24 million women in Europe with over 7 million patients worldwide presently undergo various symptom management treatments.

The Global Myomectomy Market is expected to grow at a CAGR of 6.9% during the forecast period.

Request Sample Copy at https://www.marketresearchfuture.com/sample_request/5149

Major Players in Myomectomy Market:

Some of the key players in the global market are Halt Medical, Inc. (U.K), Boston Scientific Corporation (U.S.), CooperSurgical Inc. (U.S.), C. R. Bard, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), General Electric Company (U.S.), KARL STORZ SE & Co. KG (Germany), Richard Wolf Medical Instruments (U.S.), Siemens (U.S.), AbbVie Inc. (U.S.), Bayer (Germany), Eli Lilly and Company (U.S.), Johnson & Johnson Services Inc. (U.S.) and others.

Regional Analysis

In the Americas, the market for myomectomy is found to be growing from the last few years and expected to exhibit tremendous growth during the forecast period. Rising prevalence of uterine disorders, and other reproductive health problems, emphasis on healthy lifestyle, and availability of specialized healthcare services conditions are important drivers for the growth of the market. Also, increasing demand for technologically advanced diagnostic devices and presence of major market players also influence the growth of the market.

According to the U.S. Department of Health and Human Services Office on Women's Health, about 30% of all women will get them by age 35, and around 20-80%of women will do so by age 50. For some reason, African American women are more likely to experience fibroids, and to do so at a younger age.

In Europe, the rising awareness about surgical procedures available for the treatment of uterine fibroids, and extensive research and development activities on the medical devices drive the market growth. The overall growth of healthcare diagnostic and imaging services also determine the growth of the market. Germany, U.K and France are the major contributors to the growth of the market owing to rising emphasis on the diagnosis and treatment of uterine disorders, and strengthening healthcare system.

In Asia Pacific, rising awareness about the reproductive health, and its diagnosis, and treatment of uterine disorders are major drivers for the growth of the market. Additionally, increasing healthcare expenditure, and overall demand for medical devices also accelerate the market. India & China are the largest contributors to the growth of the market owing rising emphasis on treatment of chronic diseases and increasing government support.

In the Middle East & Africa, the market is expected to show steady growth owing to low technology penetration, and rising prevalence of chronic diseases. The Middle East is the largest market for myomectomy owing to availability of specialty services in regions such as the United Arab Emirates, and Saudi Arabia.

Segmentation

The global myomectomy market is segmented on the basis of type, product, and end user.

On the basis of type, market is segmented into abdominal, hysteroscopic, laparoscopic, and robotic.

On the basis of product, the market is segmented into laparoscopic power morcellators, harmonic scalpel, laparoscopic sealer, and others.

On the basis of end user, the market is segmented into hospitals & clinics, surgical centers, medical device companies, and others.

Table of Content:

1 Report Prologue
2 Market Introduction
2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3 Research Methodology
3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4 Market Dynamics
TOC CONTINUED !

Browse Complete 110 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/myomectomy-market-5149

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Market Research Future
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: 6468459312
Website: https://www.marketresearchfuture.com/reports/myomectomy-market-5149

Source URL: https://marketersmedia.com/myomectomy-market-is-expected-to-grow-at-a-cagr-of-69-till-2023-asserts-mrfr/489712

Source: MarketersMedia

Release ID: 489712